calcification !50%, and collateral vessels compared to arteries with STO (p<0.001, all). Combination of these findings could distinguish CTO from STO (c-statistics¼0.88 (95% CI¼0.94-0.90), sensitivity¼83%, specificity¼77%, positive predictive value (PPV)¼ 55%, negative predictive value (NPV)¼93%, p<0.001). Percutaneous coronary intervention (PCI) was attempted in 342 arteries and was successful in 279 arteries (82%). CT findings could predict the unsuccessful PCI (c-statistics¼0.70 (0.65-0.75), sensitivity¼63%, specificity¼73%, PPV¼91%, NPV¼31%, p<0.001).
BACKGROUND Previous studies have shown that high and low platelet reactivity (HPR and LPR respectively) are associated with adverse events following percutaneous coronary intervention (PCI), however, therapy windows were not consistent in different studies. We aimed to determine the optimal cutoff value of platelet reactivity to prevent major adverse events (MACE) and bleeding in eastern Asian PCI patients.
METHODS Consecutive 6266 non-emergent PCI patients with aspirin and clopidogrel therapy were enrolled prospectively in the singlecenter, large-volume investigation from January to December 2013. Platelet reactivity (ADP-induced platelet-fibrin clot strength [MAADP] ) was determined by thrombelastography. MACE and Bleeding Academic Research Consortium (BARC) classification!2 bleeding were assessed between different categories of platelet reactivity and Syntax Score (SS).
RESULTS Overall, 475 MACE and 152 major bleeding (BARC grade!2) events were recorded during one year follow-up. With receiver operating characteristic (ROC) curve, we determined the cutoff values of MAADP for MACE and major bleeding (45 mm and 34mm, respectively). Then, patients were classified according to MAADP (>45 mm, 34-45 mm, and <34 mm) and we evaluated the impact of platelet reactivity on MACE and major bleeding in different Syntax Score subgroups (SS<15 and SS!15) with multivariable Cox survival analysis. In low SS group, MAADP>45 mm was the predictor of MACE (HR: 2.3; 95%CI: 1.6-5.9), but MAADP<34 mm did not show significant predicting value for major bleeding (HR: 1.3; 95%CI: 0.4-8.1). In high SS group, MAADP>45 mm was still the predictor of MACE (HR: 2.6; 95%CI: 1.3-6.3), while MAADP<34 mm show significant impact on major bleeding (HR: 1.8; 95%CI: 1.2-4.7).
CONCLUSIONS Platelet reactivity measured by thrombelastography could predict MACE and major bleeding in elective PCI patients, especially in those with high SS. Therapy window of anti-platelet drugs is narrow in eastern Asian population and further studies on tailored treatment of high-risk patients are needed. BACKGROUND Drug-eluting stents (DES) reduce angiographic restenosis and enhance event-free survival compared with bare-metal stents after implantation in coronary arteries. Limitations of current DES remain stent thrombosis and neo-atherosclerosis related to impaired healing, and repeat revascularization due to (late-) instent-restenosis. Endothelial repair can be substantially enhanced by CD34þ endothelial progenitor cells. The Combo stent combines a CD34þ antibody layer to attract endothelial progenitor cells, and thus promotes stent healing, with the abluminal release of sirolimus to prevent neointima formation and restenosis. The aim of this registry is to evaluate the long term safety and performance of the abluminal sirolimus coated bio-engineered stent in routine clinical practice.
METHODS The multicenter, prospective, clinical outcomes after deployment of the abluminal sirolimus coated bio-engineered stent post market registry, the REMEDEE Registry, is an international registry to evaluate outcomes in an all-comers population of patients undergoing percutaneous coronary intervention with (attempted) Combo stent placement in the setting of routine clinical care. Baseline demographic, clinical, and angiographic data, as well as followup data up to five years will be obtained. Clinical endpoints are defined as a composite of cardiac death, non-fatal myocardial infarction (MI) not clearly attributable to a non-target vessel, or target lesion revascularization (TLR) (percutaneous or by coronary artery bypass grafting (CABG)) in consecutive patients undergoing percutaneous coronary intervention with (attempted) Combo stent placement. All events will be adjudicated by an independent Clinical Events Committee. Cumulative event rates are estimated by a Kaplan-Meier model. RESULTS A total of 1000 patients were included in 9 European sites between June 2013 and March 2014, of which 30.4% patients presenting with acute coronary syndrome (ACS) (17.8% ST-segment elevation myocardial infarction). Mean age was 65AE11 years, 73.9% of patients are male. 184 (18.4%) patients are diabetic, 25.3% of patients have had a previous myocardial infarction, 6.8% had previous CABG. The primary endpoint of one year target lesion failure will be available at the TCT conference 2015.
CONCLUSIONS This is the first multicenter, prospective, non-interventional trial evaluating the long term clinical outcomes of patients treated with a Combo stent. 
